Enhancer-targeted CRISPR-Activation Rescues Haploinsufficient Autism Susceptibility Genes.

Area of Science:

• Neuroscience
• Genetics
• Developmental Biology

Background:

• Autism Spectrum Disorder (ASD) is a complex neurodevelopmental condition with significant genetic underpinnings.
• De novo mutations, particularly those causing gene haploinsufficiency, contribute substantially to ASD's genetic susceptibility.

Approach:

• Researchers mapped enhancers for two key autism genes, CHD8 and SCN2A.
• CRISPR-based gene activation (CRISPR-A) was employed in human stem cell-derived neurons and brain organoids.
• This method leveraged the wildtype allele and endogenous gene regulation to correct haploinsufficiency.

Key Points:

• CRISPR-A successfully and sustainably increased CHD8 and SCN2A expression in neurons and organoids.
• The gene expression rescue mitigated mutation-associated phenotypic abnormalities.
• Physiological and gene expression deficits linked to mutations were ameliorated.

Conclusions:

• Targeting enhancers for gene activation is a viable therapeutic strategy for ASD.
• This approach holds potential for treating other neurodevelopmental disorders characterized by haploinsufficiency.